The Rising Prevalence Of Cancer Boosts The Tyrosine Kinase Inhibitors Market: A Game-Changing Factor in the Tyrosine Kinase Inhibitors Market’s Future Growth
The tyrosine kinase inhibitors market size is expected to see strong growth in the next few years. It will grow to $88.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing healthcare investments, biomarker-driven therapies, drug delivery innovations, precision medicine paradigm, pediatric oncology focus. Major trends in the forecast period include resistance mitigation strategies, development of CNS-penetrant tkis, non-oncology applications, liquid biopsies for monitoring, health economic considerations.
Get Your Free Sample of The Global Tyrosine Kinase Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11957&type=smp
What are the key drivers behind the rapid expansion of the tyrosine kinase inhibitors market?
The increasing prevalence of cancer is expected to propel the growth of the tyrosine kinase inhibitors market going forward. Cancer refers to a broad collection of illnesses that begin in any organ or tissue of the body, where abnormal cells grow out of control, cross their usual boundaries to infect nearby body parts, and spread to other organs. The tyrosine kinase inhibitors are used in targeted therapy to target and kill cancer cell types by blocking tyrosine kinases that aid in preventing the growth of cancer cells. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased from 1,898,160 in 2021 to 1,958,310 in 2023, reflecting a growth of 3.16%. Therefore, the increasing prevalence of cancer is driving the growth of the tyrosine kinase inhibitors market.
What is the segmentation for the tyrosine kinase inhibitors market?
The tyrosine kinase inhibitors market covered in this report is segmented –
1) By Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Other Types
2) By Distribution Channel: Hospital Pharmacy, Independent Pharmacies, Online Pharmacies
3) By Application: Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other Applications
Subsegments:
1) By BCR-ABL Tyrosine Kinase Inhibitor: Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib
2) By Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: Gefitinib, Erlotinib, Afatinib, Osimertinib, Dacomitinib
3) By Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors: Sorafenib, Sunitinib, Pazopanib, Axitinib, Regorafenib
4) By Other Types: Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors, RET Tyrosine Kinase Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Other Emerging Tyrosine Kinase Inhibitors
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report
Who are the most influential companies in the tyrosine kinase inhibitors market?
Major companies operating in the tyrosine kinase inhibitors market include Pfizer Inc., Johnson And Johnson Private Limited., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd, Incyte Corporation, Dr. Reddy's Laboratories Ltd., Exelixis Inc., Glenmark Pharmaceuticals Ltd, Blueprint Medicines Corporation, Rigel Pharmaceuticals Inc., Deciphera Pharmaceuticals LLC, Epizyme Inc., Turning Point Therapeutics Inc., Kura Oncology Inc., ArQule Inc.
What are the most influential trends expected to drive the tyrosine kinase inhibitors market forward?
Product innovations are a key trend gaining popularity in the tyrosine kinase inhibitor market. Major companies operating in the tyrosine kinase inhibitor market are adopting new technologies to sustain their position in the market. For instance, in February 2023, Xspray Pharma AB, a Swedish pharmaceutical company, signed an agreement with EVERSANA, a US-based life sciences service company to assist with the U.S. launch and commercialization of its first innovative cancer therapy, Dasynoc, designed for treating chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Dasynoc offers a new and distinct treatment option for CML and ALL patients within the $3.5 billion U.S. market for Tyrosine Kinase Inhibitors. It represents a significant advancement for CML patients, as retrospective registry data presented at ASH 2022 revealed a 5-year overall survival rate of 79% for those treated with both a tyrosine kinase inhibitor (TKI) and proton pump inhibitor (PPI) (such as omeprazole), compared to 94% for patients on TKI alone.
What are the major regional insights for the tyrosine kinase inhibitors market, and which region holds the top position?
North America was the largest region in the tyrosine kinase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tyrosine kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Tyrosine Kinase Inhibitors Market Report 2025 Offer?
The tyrosine kinase inhibitors market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Tyrosine kinase inhibitors (TKI) refer to a class of pharmaceuticals that block several ways protein kinases signal the transduction pathway’s function. It is used in targeted therapy to target and kill cancer cell types while sparing healthy cells.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11957
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Comments
Post a Comment